Format

Send to

Choose Destination
Ann Oncol. 2017 Nov 1;28(11):2874-2881. doi: 10.1093/annonc/mdx453.

An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients.

Author information

1
Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany.
2
Regional Advisory Unit for Palliative Care, Department of Oncology, Oslo University Hospital, Oslo, and European Palliative Care Research Center (PRC), Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology and St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
3
Health Outcomes Research Unit, Faculty of Education, Ignatianum Academy, Krakow, Poland.
4
Department of Medical Education, Jagiellonian University Medical College, Krakow, Poland.
5
Department of Oncology, Oslo University Hospital, Oslo, Norway.
6
Poole Hospital NHS Foundation Trust, and The Christie NHS Foundation Trust, Manchester, UK.
7
Oncology Departments, Complejo Hospitalario de Navarra, Pamplona, Spain.
8
Chaim Sheba Medical Center, Ramat-Gan, Israel.
9
St.James's University Hospital, Leeds, UK.
10
Oncology Department, Nicosia General Hospital Cyprus, Nicosia, Cyprus.
11
Bank of Cyprus Oncology Center, Nicosia, Cyprus.
12
Azienda Ospedaliera Sant'Andrea, Rome, Italy.
13
Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei.
14
Department of Public Health, College of Public Health, National Taiwan University, Taipei, Republic of Taiwan.
15
Surgical Unit, University of Southampton, Southampton, UK.
16
Department of Internal Medicine, University Hospital Regensburg, Regensburg.
17
Department of Thoracic Surgery, Bamberg, Germany.
18
Thoracic Oncology, MOCA, Antwerp University Hospital, Edegem.
19
Quality of Life Department, EORTC, Brussels, Belgium.

Abstract

Background:

The European Organization for Research and Treatment of Cancer (EORTC) QLQ-LC13 was the first module to be used in conjunction with the core questionnaire, the QLQ-C30. Since the publication of the LC13 in 1994, major advances have occurred in the treatment of lung cancer. Given this, an update of the EORTC QLQ-LC13 was undertaken.

Methods:

The study followed phases I to III of the EORTC Module Development Guidelines. Phase I generated relevant quality-of-life issues using a mix of sources including the involvement of 108 lung cancer patients. Phase II transformed issues into questionnaire items. In an international multicenter study (phase III), patients completed both the EORTC QLQ-C30 and the 48-item provisional lung cancer module generated in phases I and II. Patients rated each of the items regarding relevance, comprehensibility, and acceptance. Patient ratings were assessed against a set of prespecified statistical criteria. Descriptive statistics and basic psychometric analyses were carried out.

Results:

The phase III study enrolled 200 patients with histologically confirmed lung cancer from 12 centers in nine countries (Cyprus, Germany, Italy, Israel, Spain, Norway, Poland, Taiwan, and the UK). Mean age was 64 years (39 - 91), 59% of the patients were male, 82% had non-small-cell lung cancer, and 56% were treated with palliative intent. Twenty-nine of the 48 questions met the criteria for inclusion.

Conclusions:

The resulting module with 29 questions, thus currently named EORTC QLQ-LC29, retained 12 of the 13 original items, supplemented with 17 items that primarily assess treatment side-effects of traditional and newer therapies.

KEYWORDS:

clinical trials; lung cancer; patient-reported outcomes (PRO); quality of life; systematic development

PMID:
28945875
DOI:
10.1093/annonc/mdx453
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for Norwegian BIBSYS system
Loading ...
Support Center